Prostate cancer

Prostate cancer
2021-01-20T00:00:00.000+08:00
Ongoing

EA8183

EA8183
Prostate Cancer

A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis

A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis

Trial overview

Topic

EA8183

Disease

Prostate cancer

Description

Primary Objective: To determine whether 12 months (52 weeks) of androgen deprivation therapy (ADT) and darolutamide improves metastasis-free survival (MFS) compared to 12 months (52 weeks) of ADT plus placebo in men with high risk prostate cancer (defined by CAPRA-S score ≥3 and a high Decipher score (>0.6) (C3+D+)) who have undergone radical prostatectomy.

Contact

Florida

Peggy Mouradian

Florida Peggy Mouradian ::: (954) 370-7555

Physicians

Eduardo B. Fernandez

MD, PhD, DABR, FACRO, FASTRO

Radiation Oncologist

Aventura (Radiation oncology) +2

Christopher T. Chen

MD, FACRO

Radiation Oncologist

Pembroke Pines (Radiation oncology) +2